Parexel has enlarged its clinical trial supply network with the opening of a distribution centre in Singapore and expansion of its Massachusetts facilities.
Eli Lilly has unveiled plans to close its Singapore R&D centre by the end of the year and relocate discovery operations to its global headquarters in the US.
GlaxoSmithKline (GSK) and the Singapore EDB are to fund eight research projects into green and sustainable production of pharmaceuticals and fine chemicals.
The Singaporean government has launched two new certification courses for clinical researchers in a bid to “deepen the pool of skilled manpower” available to the country’s rapidly expanding contract research sector.
Bayer Technology Services (BTS) has set up a new Singapore office to provide the regions’ drug and chemicals producers with engineering consultation services and micro reaction technology.
US firm 3M Drug Delivery Systems has set its sights on the Asia-Pacific region, with a new lab in Singapore which, it says, will help it better serve both local and international markets.
Singapore’s prudent spending means it can view the economic crisis as an opportunity, according to an executive director of its EDB, using saved funds to progress beyond its struggling rivals.
The Association of Southeast Asia Nations’ (ASEAN) member states will recognise each others GMP certificates as part of a programme intended to raise standards and eliminate trade barriers.
Quintiles Transnational Corp has announced an expansion of its operations in Singapore in order to meet what it described as “surging demand” in the Asia-Pacific region.
Singapore's Economic Development Board has been taking strides over
the past year to further its biomedical sciences industry and vie
for global attention amidst the other Asia Pacific players,
particularly in the field of translational...
Eisai is planning to step up its clinical research presence in Asia
and has chosen Singapore as a hub from which to coordinate its
research activities.
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
As Swiss firm Lonza announced last week that it has broken ground
at its second manufacturing site in Singapore, the region looks set
for growth in biologics manufacture with biological products due to
take centre stage in the pharma...
Biologic drug manufacturing is slowly starting to take off in
Singapore and is expected to be a key component of the country's
drug manufacturing activity in the future.
Merck Sharp & Dohme (MSD) has invested $100m to expand its
manufacturing plant in Singapore, bringing the drug giant's
investment in this budding region to over S$1bn (€0.5bn).
In the company's largest investment of its kind in Asia,
GlaxoSmithKline (GSK) has decided to build a new vaccine
manufacturing plant in Singapore, as several products in its
pipeline approach commercialisation.
Singapore's Ministry of Trade & Industry (MTI) will commit
$7.5bn (€63.1bn) over the next five years to drive R&D growth
in key industry areas such as biomedical science and increase
national R&D spending to 3 per...
Singapore's commitment to pharmaceutical research and development
goes from strength to strength after its government granted S$7.5bn
(€3.9bn) to sustain the innovation-driven growth the country has
experienced as Asia's...
Singapore's pharmaceutical output is likely to be flat this year, a
casualty of increasing pressure from generic drug firms. The
prediction, made by a Singapore official comes after the country
experienced a 40 per cent growth...
Singapore's manufacturing output, which includes pharmaceutical
technology, recorded a 33 per cent growth in 2004, achieving this
target one year ahead of schedule and exceeding projected figures
compiled in 2000.
Singapore-based biologics contract manufacturer, A-Bio Pharma has
won its first contract after entering into a process development
and clinical supply service agreement with GlaxoSmithKline's
vaccine division, GlaxoSmithKline...
Medicated chewing gum company Fertin has launched its Chlorhexidine
therapeutic chewing gum in Singapore, the second chewing gum brand
approved since the country's relaxation of its chewing gum ban.
Misssouri-based medical genomics company GenoMed will link up with
Malaysian company PhenoMed, encouraged by the Malaysian government
currently keen to push biotechnology advances in the country.